secwatch.observer — SEC 8-K summary
======================================

Issuer:     INVO Fertility, Inc. (IVF)
CIK:        0001417926
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001493152-23-028451
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INVO Bioscience Q2 revenue up 116% to $316K; closes WFI acquisition for $10M
----------------------------------------------------------------------------

- Revenue $315,902 (+116% YoY); clinic revenue $254,364 (+126%); all clinics $712,433 (+145%).
- Acquired Wisconsin Fertility Institute for $10M (3-yr payment); WFI 2022 rev $5.4M, net income $1.7M.
- Adjusted EBITDA -$1.6M (vs. -$2.2M); cash $0.1M at 6/30; $4.5M raised in public offering post-Q.
- Expects clinic ops cash flow positive in Q3 2023, overall operating cash flow positive in 2024.
- Received FDA 510(k) clearance for expanded use of INVOcell device.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1417926/000149315223028451/0001493152-23-028451-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1417926/000149315223028451/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-028451

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer